Needham Maintains Buy on Xenon Pharmaceuticals, Maintains $62 Price Target

Benzinga · 05/10 22:02
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $62 price target.